What Artedil Treats: Main Uses and Benefits

Artedil (Manidipine Dihydrochloride) is a medicine generally applied in contexts marked by chronic systemic imbalance (essential hypertension). The medication is commonly used to address persistently elevated systolic and diastolic blood pressure readings in adult patients. Its application is relevant for managing conditions that involve an increased systemic burden, including essential hypertension, and is used in situations involving Type 2 Diabetes Mellitus or isolated systolic hypertension in older adults.

The core therapeutic benefit is that it is used for managing sustained, 24-hour symptom control related to elevated arterial pressure. This supports the long-term goal of the patient by contributing to lowering the overall long-term risk associated with unmanaged high pressure. In scenarios where additional management of discomfort is required, such as concerns regarding peripheral edema, this medicine generally contributes to improved comfort during symptomatic periods.

“This medicine is commonly used to help with symptoms related to chronic systemic imbalance, and may assist with maintaining functional stability by offering supportive relief.”

Quick Fact: Use in Elevated Pressure
Primary Condition Focus	Essential hypertension (primary high blood pressure)
Symptom Category	Persistent elevated systolic and diastolic blood pressure readings
Clinical Scenario	Long-term chronic management and supportive therapy in high-risk patients
Key Benefit	Contributes to stable, 24-hour pressure control and supports general well-being

Regulatory References

1. Norwegian Medicines Agency ATCDDD

Artedil (Manidipine Dihydrochloride) is officially approved for use in adult patients with essential hypertension. However, regulatory documents establish strict contraindications and use limitations based on age, organ function, and pre-existing medical conditions.

Contraindications: Who Must Not Use Artedil

The medicine is contraindicated and must not be used by patients with:

• Known hypersensitivity to manidipine or other dihydropyridines.
• Severe renal failure (creatinine clearance < 10 ml/min) or moderate to severe liver failure.
• Unstable angina, a history of myocardial stroke within the last four weeks, or untreated congestive heart failure.
• Women who are pregnant or breastfeeding.
• Children (paediatric age) due to a lack of clinical experience.

Restricted or Conditional Use

Caution is required in specific populations, and use may be restricted. This includes elderly patients, who may require reduced starting doses. Special precautions are also necessary for patients with mild hepatic impairment or specific cardiac conditions like left ventricular failure or sick sinus syndrome without a pacemaker.

Artedil may interact with various medicines and other products, potentially increasing its effects on blood pressure or altering its concentration in the body. Consult with a healthcare professional regarding all co-administered products.

Interactions with Medicines

The primary risk of drug-drug interactions involves an enhanced blood pressure-lowering effect when Artedil is taken alongside other antihypertensive medicines, such as diuretics and beta-blockers. This requires monitoring and potential dose adjustment to maintain a safe blood pressure level.

Other clinically significant interactions are due to the effect on the metabolism of Artedil's active substance. Products that inhibit the enzymes responsible for its breakdown can increase its levels in the bloodstream. These include certain antibiotics like clarithromycin and erythromycin, some antifungal agents, and protease inhibitors.

Conversely, agents that accelerate the metabolism of Artedil, such as rifampicin (an antibiotic), may reduce its effectiveness. Caution and potential dose adjustment are also required when Artedil is co-administered with digoxin and cimetidine.

Interactions with Products

Grapefruit juice must not be consumed with this medication. Components in grapefruit juice can significantly inhibit the metabolism of Artedil in the intestines, which can lead to excessive concentrations of the drug in the body and a potentially dangerous drop in blood pressure. Additionally, consuming alcohol can enhance the overall blood pressure-lowering effect of Artedil.

Direct Inhibition of Vascular Smooth Muscle Contraction

Manidipine (Artedil) exerts its principal action by blocking L-type voltage-gated calcium channels ( Cav1) on the smooth muscle cells of peripheral arteries. This blockade prevents the necessary influx of extracellular calcium ions ( Ca^2+) into the cells, thus interrupting the molecular cascade that dictates muscle contraction. This mechanism leads to widespread arterial vasodilation (widening), which is the primary physiological adjustment that reduces the body's total peripheral resistance.

---

Dual Modulation of Renal Blood Flow Pathways

The mechanism involves a specific interaction with both Cav1 channels and T-type calcium channels ( Cav3), particularly within the arterioles of the kidney. This dual channel blockade promotes relaxation and widening in both the incoming (afferent) and outgoing (efferent) renal arteries. This action results in a modulation of pressure within the kidney's filtration unit, contributing to a unique physiological effect on renal hemodynamics.

---

Secondary Metabolic Pathway Engagement

Beyond its channel-blocking role, Manidipine demonstrates a secondary mechanistic activity as a partial agonist at the nuclear receptor PPARgamma. This interaction involves modulating genetic expression patterns related to metabolic processes. This non-hemodynamic activity results in modulation of systemic metabolic pathways; the mechanism operates across both vascular and metabolic pathways.

Administration Guidelines for Artedil (Manidipine Dihydrochloride)

Artedil is a film-coated tablet that is administered orally and is intended for long-term use. Standard guidelines define the route, starting dose, maximum dose, timing, and necessary adjustments for specific patient populations.

---

Dosing and Administration Schedule

Instruction	Detail (Administration Principle)
Route of Administration	Oral
Dosing Schedule (Adults)	The starting dose is 10 mg once daily. If the effect is insufficient after 2 to 4 weeks of treatment, the dosage may be increased to the maximum recommended dose of 20 mg once daily.
Timing and Intake	The tablet must be taken once daily in the morning, specifically after breakfast. The tablet should be swallowed with liquid and without chewing.
Forbidden Co-Administration	Administration must not occur with grapefruit juice.

---

Procedural Adjustments and Special Conditions

Dose limitations are based on physiological factors:

• Mild Hepatic Impairment: The daily dose should not exceed 10 mg due to the drug's extensive metabolism in the liver.
• Older Adults (Geriatric): A starting dose of 10 mg is recommended, and dose reductions should be considered due to slowing metabolic processes.
• Renal Impairment: No initial dose adjustment is required for mild to moderate impairment, but caution is advised if increasing the dose above 10 mg daily.

If a dose is missed, the standard practice is to take it as soon as possible, but to skip the dose entirely if it is almost time for the next scheduled dose; doubling the dose is not permitted. The score line on the tablet is intended only to facilitate breaking for ease of swallowing and is not intended for dividing the tablet into equal doses.

Artedil: Research Evidence and Overview of Studies (Manidipine Hydrochloride)

This summary provides an overview of the types of research that have been conducted on Artedil and what those studies examined. The information is presented to reflect the available data and the areas where research is still evolving, without offering any medical advice or suggesting individual treatment outcomes.

---

Evidence for Use in Essential Hypertension

Artedil was studied for use in adult patients who have high blood pressure, a condition marked by functional limitations. The research explored this primarily through short-term randomized controlled trials (RCTs) and multicenter studies. These studies were observed in populations of hypertensive adults, with researchers monitoring specific outcomes related to systemic or functional imbalance.

Studies monitored measurements of systolic and diastolic blood pressure, which are physiological outcomes linked to inflammatory or irritative states. Findings report how symptoms evolved in the observed populations regarding blood pressure changes over the treatment period. The research also examined laboratory markers and the incidence of reported events within the study populations.

---

Comparative Studies and Trial Design

The research environment for Artedil included studies focusing on episodes where symptoms become more noticeable and trials that was evaluated in a comparison of Artedil to other established treatments, as well as to an inactive substance (placebo). This research explored outcomes related to systemic or functional imbalance across these different groups. These studies also research monitored measurements of blood pressure changes in patients using Artedil alone versus those using it in combination with a second agent.

---

Long-Term Follow-Up and Durability of Study Outcomes

When reviewing the evidence, it is important to note that the long-term effects are not fully established. Research so far has concentrated on short-term follow-up durations and intermediate-term assessment points, typically spanning up to a few months. The follow-up durations were limited in many of the key studies. The available data findings describe group patterns, not personal outcomes regarding the sustained effects of Artedil over many years.

---

What Research Limitations and Uncertainties Remain

A thorough review of the evidence highlights several areas where certainty remains low and further research is ongoing. Sample sizes were modest in some comparative studies, which can limit the ability to generalize the findings to the larger patient community. Furthermore, the focus on physiological measures like blood pressure means there are limited information for long-term outcomes regarding major clinical events. Research to address these evidence gaps is ongoing.

Key Studies & References

1. Cardiplot - National Drug Information (Summary of Product Characteristics)

Common questions about Artedil (FAQ)

---

Q: Can Artedil be taken alongside non-prescription pain relievers like ibuprofen or acetaminophen?

Official documents list certain antibiotics, antifungals, and other prescription blood pressure medicines as potential interacting substances.

However, regulatory information does not specifically name or exclude common non-prescription pain relievers like ibuprofen or acetaminophen in the primary interaction warnings. Information regarding co-administered products is generally necessary for a healthcare professional to determine suitability.

---

Q: Does Artedil interact with common vitamins or herbal supplements?

Official patient information advises users to be aware of the potential for interaction when taking the medicine alongside dietary supplements or certain herbal products.

Regulatory documents describe a general caution regarding dietary supplements due to the potential for enhancement or diminishment of the medicine’s effect.

---

Q: Is there information on the safety of Artedil for older adults (seniors)?

Regulatory documents address the use of this medicine in older adults, stating that use may be conditional.

Official prescribing information notes that dose reductions are typically considered for older adults due to known differences in how the medicine is processed in the body.

---

Q: Can women who are pregnant or planning to become pregnant use Artedil?

Official documents strictly state that Artedil is contraindicated, meaning it must not be used, by women who are pregnant or who are currently breastfeeding.

Determining suitability during the planning stage of pregnancy is a factor that is generally assessed in consultation with a healthcare professional.

---

Q: How long does it typically take before a person notices the effects of Artedil?

The medicine is described in scientific literature as having a gradual onset of action in the body.

In the administration schedule, the physiological effect of the medicine is typically evaluated after 2 to 4 weeks of continuous treatment, which is the interval when adjustments may be considered.

---

Q: What is the expected duration of action for a single dose of Artedil?

Artedil is designed to be taken on a once-daily schedule.

Research indicates that the medicine is formulated to have a long duration of action, effectively maintaining its blood pressure-reducing effect throughout the entire 24-hour dosing period.

---

Q: How long is Artedil generally taken for—short-term or long-term?

According to regulatory guidance, Artedil is an antihypertensive agent intended for the sustained and long-term management of elevated arterial pressure (essential hypertension) in adults.

---

Q: Will taking Artedil affect my ability to drive or operate machinery?

Official warnings state that the medicine may cause adverse reactions such as dizziness and lightheadedness, which are consistent with its blood pressure-lowering effects.

Official information indicates that activities like driving or operating machinery may require caution due to the documented potential for dizziness or lightheadedness.

---

Q: Does Artedil have a high potential for interaction with blood pressure medications?

Official drug information describes a high potential for interaction when Artedil is taken with other medicines intended to lower blood pressure, such as diuretics and beta-blockers.

This interaction is noted as a primary risk that can lead to an enhanced or increased overall blood pressure-lowering effect.

---

Q: How does Artedil differ from other common medicines used for the same purpose?

The medicine is classified as a dihydropyridine calcium channel blocker.

The medicine is described pharmacologically as having a dual inhibitory action on both L-type and T-type calcium channels, which is a characteristic noted in research.

---

Q: Are there any known severe or rare side effects associated with Artedil?

Official documentation lists both rare and very rare events associated with the medicine.

Rare events include jaundice and chest pain. Very rare events include specific changes in gum tissue (gingival hyperplasia) and myocardial stroke.

---

Q: Is Artedil a controlled substance?

Artedil is a prescription-only medicine.

It belongs to the dihydropyridine calcium channel blocker class, a group of drugs that is not typically listed as a scheduled controlled substance in official regulatory classifications.

---

Q: Will Artedil affect the results of any common lab tests?

Clinical studies have examined the medicine’s potential effects on specific endocrine markers and laboratory values, such as plasma renin activity and aldosterone levels.

No significant changes were noted in those levels during the treatment period observed in the studies.

---

Q: How quickly does Artedil leave the body after the last dose?

The rate at which the medicine is eliminated from the body is measured by its elimination half-life.

Official data indicates this half-life has been reported to be dose-dependent, typically ranging from approximately 4 to 8 hours. The medicine is primarily cleared from the body after being extensively broken down (metabolized).

---

Q: What is the recommended method for storing Artedil?

Official labeling mandates specific conditions to maintain the medicine’s integrity.

Official labeling specifies that the tablets should be stored at a temperature below 30 C, protected from light, heat, and moisture, and kept in the original container, out of the sight and reach of children.

---

Q: What should I do if I feel like Artedil is not working for me?

The official dosing schedule involves reassessing the medicine’s effect after 2 to 4 weeks of treatment.

If the effect is deemed insufficient at that point, regulatory guidelines allow for a possible adjustment to the dosage by a healthcare professional.

---

Q: Can Artedil cause sun sensitivity or skin reactions?

Official documentation lists several possible adverse reactions affecting the skin.

These include rash, itch, and also photosensitivity, which is the risk of increased sensitivity to sunlight.

---

Q: Do any official documents discuss Artedil's use in patients with diabetes?

Yes, studies have specifically examined the medicine’s use in patients with both hypertension and diabetes.

In these populations, the medicine has been observed to have neutral effects on both glucose and lipid metabolism.

---

Q: Is Artedil known to be safe for long-term use?

The medicine is formally intended for the long-term management of high blood pressure.

However, official research overviews indicate that follow-up durations in key studies were limited, and long-term effects beyond short- and intermediate-term assessment points are not fully established.

---

Q: Are there specific instructions for how to stop taking Artedil?

Official patient information states that the medicine should not be stopped without prior direction from a health care professional.

The decision to discontinue or change the treatment regimen is generally made under the guidance of a health care professional.

---

Q: Is it normal to feel slightly dizzy when first starting Artedil?

Dizziness and lightheadedness are documented as common adverse reactions, which is a physiological outcome of the medicine successfully lowering blood pressure.

Official information advises caution as this effect may be most noticeable when first starting treatment or when rising from a sitting or lying position.

Artedil Storage and Disposal: Official Regulatory Information

The official labeling for Artedil (Manidipine Dihydrochloride) mandates specific conditions to maintain its pharmaceutical integrity and safety. The tablets must be stored at a temperature below 30°C and require strict protection from environmental elements including light, heat, and moisture. It is required that the medicine be kept in its original container and stored out of the sight and reach of children.

Classification	Official Storage Constraint
Temperature Range	Below 30°C
Protection	Protect from light, heat, and moisture
Child Safety	Keep out of the sight and reach of children

Disposal of any expired or unneeded Artedil must adhere to official pharmaceutical waste guidelines. Patients are instructed to ask the pharmacist or medical facility for guidance on how to properly discard the medicine. Disposal must be in accordance with local regulatory requirements; the medicine should not be thrown into household waste or wastewater unless specifically authorized by local authorities.